Vertex PharmaceuticalsVRTXEarnings & Financial Report
Nasdaq · Health Care · Biotechnology
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| OF ABOVE PERSONS | 10.00% | 25.9M | ▲ +1.40pp | 2024-04-10 |
| The Vanguard Group | 8.65% | 22.3M | — | 2024-02-13 |
| BlackRock, Inc. | 8.50% | 21.9M | — | 2024-01-25 |
| FMR LLC | 5.04% | 13.0M | — | 2024-02-09 |
Insider Transactions
Net 90d: −$31.17M · buys $0 / sells $31.17MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | Joy Liu | EVP and Chief Legal Officer | Sell (open market) | 978 | $449.17 | $439.3K |
| 2026-03-27 | Carmen Bozic | EVP and CMO | Sell (open market) | 2.3K | $450.95 | $1.05M |
| 2026-03-13 | Carmen Bozic | EVP and CMO | Sell (open market) | 2.3K | $481.79 | $1.12M |
| 2026-03-11 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell (open market) | 2.6K | $498.42 | $1.31M |
| 2026-03-04 | McKechnie Duncan | EVP, Chief Commercial Officer | Sell (open market) | 2.4K | $475.30 | $1.16M |
| 2026-03-02 | Joy Liu | EVP and Chief Legal Officer | Sell (open market) | 892 | $495.96 | $442.4K |
| 2026-02-27 | Reshma Kewalramani | CEO & President | Sell (open market) | 400 | $479.75 | $191.9K |
| 2026-02-27 | Reshma Kewalramani | CEO & President | Sell (open market) | 120 | $481.50 | $57.8K |
| 2026-02-27 | Reshma Kewalramani | CEO & President | Sell (open market) | 240 | $482.84 | $115.9K |
| 2026-02-27 | Reshma Kewalramani | CEO & President | Sell (open market) | 2.5K | $487.13 | $1.22M |
1–10 of 29
Page 1 / 3